Clinical translation of epigenome editing technologies

Area of Science:

• Biotechnology
• Genetics
• Molecular Biology

Background:

• CRISPR/Cas-based epigenome editing enables precise control of gene expression and epigenetic states.
• It offers a safer alternative to conventional genome editing, minimizing genotoxicity risks.
• Epigenome editing is crucial for understanding and treating diseases linked to transcriptional and epigenetic dysregulation.

Purpose of the Study:

• To review recent advances in CRISPR/Cas-based epigenome editing technologies.
• To discuss challenges and progress in clinical deployment, including delivery, performance, and safety.
• To highlight the potential of epigenome editing for biomedical discoveries and therapies.

Main Methods:

• Review of recent scientific literature and clinical trial progress in CRISPR/Cas epigenome editing.
• Analysis of advancements in Cas chassis, effector domain engineering, and targeting specificity.
• Exploration of strategies to enhance delivery, reduce immunogenicity, and improve safety profiles.

Main Results:

• Significant enhancements in precisely controlling gene expression timing, levels, and durations.
• Development of compact Cas systems and engineered effectors for efficient delivery and specificity.
• Progress in tailoring targeting discrimination and developing effector domains with high specificity and low toxicity.

Conclusions:

• CRISPR/Cas epigenome editing is a powerful platform technology for biological discovery and innovation.
• It holds immense promise for novel therapeutics, cell therapies, and regenerative medicine.
• Continued research addressing delivery, performance, and safety is paving the way for widespread clinical application.